Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sangpanasine
- Development stage
- Preclinical
- Lead developer
- Jiangsu Jibeier Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sangpanasine (桑辘碱) is a natural product-derived small molecule being developed by Jiangsu Jibeier Pharmaceutical for the treatment of type 2 diabetes. Derived from mulberry alkaloids, the compound functions as an alpha-glucosidase inhibitor. By inhibiting alpha-glucosidase enzymes in the brush border of the small intestine, Sangpanasine slows the breakdown of complex carbohydrates into glucose, thereby delaying glucose absorption and reducing postprandial blood glucose excursions. The drug is currently in preclinical development and is formulated as an oral capsule.
- Other names
- 桑辘碱Sangpanasine CapsulesMulberry Alkaloid Capsules桑辘碱胶囊
02
Targets
Sucrase-Isomaltase
Beyond the preview
Go deeper on Sangpanasine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sangpanasine.